The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.

The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.

The present invention relates to Regentide-034 and Regentide-041 and, more specifically, to a use of a mixture of Regentide-034 and Regentide-041 for improving skin conditions. A mixture of Regentide-034 and Regentide-041 according to the present invention is free of cytotoxicity and has remarkable effects of promoting cell proliferation and collagen synthesis, inhibiting elastase activity, and suppressing ultraviolet light-induced cell death and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

The present invention relates to Regentide-034 and Regentide-041 and, more specifically, to a use of a mixture of Regentide-034 and Regentide-041 for improving skin conditions. A mixture of Regentide-034 and Regentide-041 according to the present invention is free of cytotoxicity and has remarkable effects of promoting cell proliferation and collagen synthesis, inhibiting elastase activity, and suppressing ultraviolet light-induced cell death and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.

The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.

The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine.

The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine.

To develop a universal and long-lasting influenza or other pathogens vaccine has been a mission impossible goal in the life science and health field. Applicants disclose, herein, vaccines prepared against SARS-COV-2, an influenza A strain vaccine prepared from a 1934 influenza virus (A/PR/8/34 H1N1, Puerto Roca, 1934), and an influenza B strain vaccine prepared from a 1940 influenza virus. The disclosed vaccine induces production of broadly neutralizing antibodies in mice. The presently disclosed vaccine is able to inhibit two other influenza A strains: a 2009 influenza H1N1 virus collected from Los Angeles (A/California/07/2009) and a 2014 influenza H3N2 virus collected from Hong Kong (A/Hongkong/4801/2014). Applicants also describe an influenza B strain vaccine prepared from a B strain virus from a 1940 patient in USA (B/L11/40). The B strain vaccine also produced broadly neutralizing antibodies, in this case against a B strain from Colorado 2017 (B/Colorado/2017). Applicant's methods and compositions are not only useful in creating influenza vaccines with broad activity against other influenza subtypes but also be efficient to generate long-lasting SARS-CoV-2 vaccines against emerging new variants either through recombined protein antigens from SARS-CoV-2 or inactivated SARS-CoV-2 virus.

Provided herein is an inhibitor compound targeting Hip1, with the inhibitor compound comprising a tripeptide targeting sequence that directs the compound to the active site of Hip1 and a C-terminal electrophilic warhead conjugated to the targeting sequence, the warhead configured to inactive the enzyme.